Action on Access

Action on Access
Name	Action on Access
Founded	2013
Founder	Not applicable
Type	Non-profit advocacy initiative
Headquarters	United Kingdom
Region served	Global
Website	Not provided

Action on Access is a policy advocacy initiative focused on improving access to essential medicines, vaccines, diagnostics, and health technologies worldwide. It coordinates research synthesis, stakeholder engagement, and strategic campaigns aimed at influencing international institutions, pharmaceutical manufacturers, national ministries, and philanthropic organizations. The initiative engages with multilateral forums, regulatory agencies, and civil society to promote equitable access and affordability.

Background and Objectives

Action on Access emerged amid sustained debates over intellectual property regimes, pricing strategies, and regulatory pathways affecting access to health technologies. It articulates objectives to expand World Health Organization policy uptake, reform aspects of the Agreement on Trade-Related Aspects of Intellectual Property Rights overseen by the World Trade Organization, and accelerate technology transfer in collaboration with entities such as the United Nations and the World Bank. The initiative targets structural barriers that have been central to discussions at the Gavi, the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and national procurement agencies, seeking to influence outcomes related to the Patent Cooperation Treaty and mechanisms discussed within the World Intellectual Property Organization.

Campaigns and Initiatives

Action on Access runs campaigns that intersect with major global health events and advocacy moments, engaging with stakeholders around the Seventy-Third World Health Assembly, the United Nations General Assembly high-level meetings on health, and technical consultations convened by the European Medicines Agency and the U.S. Food and Drug Administration. Initiatives have targeted pricing transparency by campaigning alongside organizations active in the Access to Medicine Index discourse and have advocated for expanded use of compulsory licensing provisions referenced in Doha Declaration on the TRIPS Agreement and Public Health. Campaigns also include promoting voluntary licensing models used by entities like the Medicines Patent Pool and advocating for pooled procurement mechanisms similar to those employed by PAHO Revolving Fund and regional blocs such as the African Union procurement efforts.

Organizational Structure and Partnerships

The initiative operates through a consortium model that brings together non-governmental organizations, academic centers, think tanks, and professional associations. Partners include advocacy groups aligned with the Treatment Action Campaign, research institutions with ties to London School of Hygiene & Tropical Medicine and Harvard T.H. Chan School of Public Health, and legal clinics that interact with the Oxford University Global Health Network. It engages with philanthropic actors such as the Bill & Melinda Gates Foundation in coordination contexts and consults with policy-focused entities like the Chatham House and the Brookings Institution. Governance typically incorporates advisory boards with representatives from civil society organizations associated with the International Treatment Preparedness Coalition and regional networks linked to the Asia Pacific Network of People Living with HIV.

Funding and Financial Model

Funding sources for the initiative reflect a mix of philanthropic grants, foundation agreements, and charitable donations. Major funders commonly include global health foundations and philanthropic arms of multilateral organizations that have previously supported initiatives connected to Clinton Health Access Initiative projects and programmatic work aligned with Médecins Sans Frontières advocacy. Financial management models emphasize grant-funded project cycles and in-kind contributions from academic partners, with occasional contractual research commissioned by supranational agencies such as the European Commission's Directorate-General for International Partnerships. The initiative also coordinates pooled funding approaches akin to mechanisms used by the Global Financing Facility.

Impact and Criticism

Action on Access has influenced policy dialogues at forums like the World Health Assembly and contributed to increased visibility for pricing transparency and licensing reform in debates involving the World Trade Organization and World Intellectual Property Organization. It has been credited by some stakeholders with helping to catalyze discussions on voluntary licensing and technology transfer during health emergencies referenced in meetings with the International Monetary Fund and the G20. Criticism has arisen from industry groups and some national delegations who argue that advocacy efforts risk undermining patent incentives that entities such as Pfizer, GlaxoSmithKline, and Johnson & Johnson assert are necessary for innovation. Other commentators reference tensions evident in dialogues with regional manufacturers like Biocon and multinational research collaborations involving institutions such as National Institutes of Health.

Regional and Global Programs

Regionally, the initiative engages with actors across Africa, Asia, Latin America, and Europe, interfacing with regional bodies including the African Union, the Pan American Health Organization, and the Association of Southeast Asian Nations. Programs have included support for national policy development in collaboration with ministries such as the Ministry of Health (India) and advisory inputs for procurement reforms referenced by the South African National Department of Health. On the global stage, it participates in technical working groups with the World Health Organization, contributes to policy briefs circulated at the United Nations Economic and Social Council sessions, and collaborates with global procurement entities like UNICEF in efforts to align supply strategies with equity goals.

Category:Global health organizations